Ulka Vaishampayan, MD

Articles

Combination PARPi Strategies in Metastatic CRPC: Interpreting Data From Clinical Trials

August 8th 2023

Key opinion leaders in metastatic castration-resistant prostate cancer management review a subset of clinical trials focused on combination strategies with PARP inhibitors.

Advent of PARP Inhibitors in Metastatic CRPC

August 1st 2023

Moving on to discuss metastatic castration-resistant prostate cancer, panelists highlight the evolving role of PARP inhibition in this setting.

Evolving Treatment Landscape of Nonmetastatic Castration-Resistant Prostate Cancer

August 1st 2023

Comprehensive insight to key treatment modalities for patients with nonmetastatic castration-resistant prostate cancer and how to select amongst them.

Informing Systemic Therapy Selection With Negative Data in HSPC

July 25th 2023

A brief conversation on negative clinical trial readouts and how they may help to inform optimal treatment pathways for patients with metastatic hormone-sensitive prostate cancer.

What is the Role of Locoregional Therapy in Metastatic HSPC?

July 25th 2023

Following their discussion on systemic therapy, expert panelists consider the value of locoregional therapy for a subset of patients with metastatic hormone-sensitive prostate cancer.

Systemic Treatment Armamentarium in Metastatic HSPC

June 26th 2023

Shared insight on the range of systemic therapy options available to patients who present with metastatic hormone-sensitive prostate cancer.

Overview of Metastatic HSPC: Diagnosis and Risk Stratification

June 26th 2023

Opening their first module on metastatic hormone-sensitive prostate cancer, panelists consider optimal diagnostic and risk stratification strategies for when a patient presents in clinic.

Future Directions in the Management of Renal Cell Carcinoma

November 10th 2022

Shared insight on the evolving treatment landscape of renal cell carcinoma and expectations for future evolution in the paradigm.

Novel Treatment Strategies in Non-Clear Cell Renal Cell Carcinoma

November 10th 2022

Before closing out there review of non–clear cell RCC management, expert oncologists highlight novel therapeutic strategies and ongoing clinical trials.

Systemic Therapy in the Treatment of Non-Clear Cell RCC: The Evolving Landscape

November 3rd 2022

Moving on to discuss the management of non–clear cell renal cell carcinoma, panelists consider cornerstone treatment options in this setting.

Advanced Clear Cell RCC: Optimal Selection and Sequencing of Second-Line Therapy

November 3rd 2022

Comprehensive insight to the optimal selection and sequencing of therapy for advanced clear cell RCC in the second-line setting and beyond.

Treatment Options for Advanced Clear Cell RCC in the Second-Line and Beyond

October 27th 2022

Centering their discussion on the second-line setting, expert oncologists review mainstay second-line therapies for advanced clear cell RCC.

Is There a Role for Adjuvant Therapy in Advanced Clear Cell RCC?

October 27th 2022

Expert perspectives on key clinical trials studying first-line adjuvant therapy in patients with advanced clear cell renal cell carcinoma.

First-Line Therapy in Advanced Clear Cell RCC: Novel Triplet Regimens

October 20th 2022

Focusing on novel first-line triplet therapy combinations, panelists consider which regimens may find a role in the management of advanced clear cell RCC.

Advanced Clear Cell RCC: Quality of Life Data in First-Line Clinical Trials

October 13th 2022

Before closing out their review of mainstay combination therapy in the first-line setting of advanced clear cell RCC, panelists reflect on available quality of life data.

Treating Patients with Clear Cell RCC with Brain Metastases or Sarcomatoid Disease

October 13th 2022

Focused discussion on brain metastases or sarcomatoid disease in advanced clear cell RCC and the selection of first-line treatment regimens.

Advanced Clear Cell RCC: Role of Site of Metastases in Selecting First-Line Therapy

October 6th 2022

Shared insight on the importance of sites of metastases and how they may impact first-line treatment selection in advanced clear cell RCC.

Selecting the Appropriate First-Line Therapy in Advanced Clear Cell RCC

October 6th 2022

Centering conversation on systemic therapy, panelists review trial data behind the first-line combination regimens for patients with advanced clear cell RCC.

What is the Role of Nephrectomy in Advanced Clear Cell RCC?

September 29th 2022

Comprehensive insight to the role of nephrectomy over systemic therapy in patients who receive a diagnosis of advanced clear cell RCC.

Overview on Clear Cell Renal Cell Carcinoma: Prevalence and Prognosis

September 29th 2022

Expert oncologists open their discussion on advanced clear cell RCC by identifying its prevalence and prognoses before moving into treatment considerations.